Search Results

There are 5531 results for: content related to: High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias

  1. Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations

    Movement Disorders

    Volume 16, Issue 5, September 2001, Pages: 858–866, William Koller, Andrew Lees, Miroslava Doder, Mariese Hely and the Tolcapone/Pergolide Study Group

    Version of Record online : 20 SEP 2001, DOI: 10.1002/mds.1175

  2. Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study

    Movement Disorders

    Volume 21, Issue 3, March 2006, Pages: 343–353, Wolfgang H. Oertel, Erik Wolters, Cristina Sampaio, Santiago Gimenez-Roldan, Bruno Bergamasco, Max Dujardin, Donald G. Grosset, Guy Arnold, Klaus L. Leenders, Hans-Peter Hundemer, Alberto Lledó, Andrew Wood, Paul Frewer and Johannes Schwarz

    Version of Record online : 6 OCT 2005, DOI: 10.1002/mds.20724

  3. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to sinemet® in Parkinson's disease

    Movement Disorders

    Volume 9, Issue 1, 1994, Pages: 40–47, Dr. C. W. Olanow, S. Fahn, M. Muenter, H. Klawans, H. Hurtig, M. Stern, I. Shoulson, R. Kurlan, J. D. Grimes, J. Jankovic, M. Hoehn, C. H. Markham, R. Duvisin, O. Reinmuth, H. A. Leonard, E. Ahlskog, R. Feldman, L. Hershey and M. D. Yahr

    Version of Record online : 12 OCT 2004, DOI: 10.1002/mds.870090107

  4. A review of the efficacy of the dopamine agonists pergolide and bromocriptine in the treatment of Parkinson's disease

    European Journal of Neurology

    Volume 4, Issue 6, November 1997, Pages: 537–543, V. Nohria and A. Partiot

    Version of Record online : 20 JAN 2011, DOI: 10.1111/j.1468-1331.1997.tb00403.x

  5. DA agonists - Ergot derivaties: Pergolide

    Movement Disorders

    Volume 17, Issue S4, July/August 2002, Pages: S79–S82,

    Version of Record online : 29 JUL 2002, DOI: 10.1002/mds.5566

  6. Physiologic disposition of pergolide

    Clinical Pharmacology & Therapeutics

    Volume 30, Issue 2, August 1981, Pages: 258–265, Alan Rubin, Louis Lemberger and Patricia Dhahir

    Version of Record online : 25 AUG 1981, DOI: 10.1038/clpt.1981.157

  7. Pergolide compared with bromocriptine in Parkinson's disease: A multicenter, crossover, controlled study

    Movement Disorders

    Volume 9, Issue 4, 1994, Pages: 431–436, Dr. G. Pezzoli, E. Martignoni, C. Pacchetti, V. A. Angeleri, P. Lamberti, A. Muratorio, U. Bonuccelli, M. De Mari, N. Foschi, E. Cossutta, F. Nicoletti, F. Giammona, M. Canesi, G. Scarlato, T. Caraceni and E. Moscarelli

    Version of Record online : 12 OCT 2004, DOI: 10.1002/mds.870090409

  8. The levodopa dose-sparing capacity of pergolide compared with that of bromocriptine in an open-label, crossover study

    European Journal of Neurology

    Volume 3, Issue 1, January 1996, Pages: 44–49, J. Boas, J. Worm-Petersen, E. Dupont, B. Mikkelsen and L Wermuth

    Version of Record online : 20 JAN 2011, DOI: 10.1111/j.1468-1331.1996.tb00188.x

  9. Pergolide, a potent long-acting dopamine-receptor agonist

    Clinical Pharmacology & Therapeutics

    Volume 27, Issue 5, May 1980, Pages: 642–651, Louis Lemberger, Ross Crabtree and J Thomas Callaghan

    Version of Record online : 11 MAY 1980, DOI: 10.1038/clpt.1980.91

  10. A “combined” levodopa test as a useful method for evaluating the efficacy of dopamine agonists: Application to pergolide and bromocriptine

    Movement Disorders

    Volume 10, Issue 5, September 1995, Pages: 668–671, Dr. A. M. Bonnet, I. Serre, R. Marconi, Y. Agid and B. Dubois

    Version of Record online : 12 OCT 2004, DOI: 10.1002/mds.870100522

  11. The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease

    Movement Disorders

    Volume 14, Issue 6, November 1999, Pages: 940–946, J. Eric Ahlskog, Ryan J. Uitti, Michael K. O'Connor, Demetrius M. Maraganore, Joseph Y. Matsumoto, Kathy F. Stark, Margaret F. Turk and Omer L. Burnett

    Version of Record online : 25 JAN 2001, DOI: 10.1002/1531-8257(199911)14:6<940::AID-MDS1005>3.0.CO;2-Y

  12. Microbial transformations of pergolide to pergolide sulfoxide and pergolide sulfone

    Journal of Pharmaceutical Sciences

    Volume 72, Issue 7, July 1983, Pages: 733–736, Robert V. Smith, Patrick J. Davis and Kathleen M. Kerr

    Version of Record online : 16 SEP 2006, DOI: 10.1002/jps.2600720704

  13. Development of selective dopamine receptor agonists as novel cardiovascular drugs

    Drug Development Research

    Volume 4, Issue 3, 1984, Pages: 285–300, Dr. Richard A. Hahn

    Version of Record online : 5 OCT 2004, DOI: 10.1002/ddr.430040306

  14. Pergolide in late-stage Parkinson disease

    Annals of Neurology

    Volume 12, Issue 3, September 1982, Pages: 243–247, A. E. Lang, N. Quinn, S. Brincat, C. D. Marsden and Dr J. D. Parkes

    Version of Record online : 16 OCT 2004, DOI: 10.1002/ana.410120305

  15. The use of pergolide, a potent dopamine agonist, in parkinson's disease

    Clinical Pharmacology & Therapeutics

    Volume 32, Issue 1, July 1982, Pages: 70–75, Abraham N Lieberman, Menek Goldstein, Andreas Neophytides, Morton Leibowitz, Govindan Gopinathan, Russell Walker and Virginia Pact

    Version of Record online : 22 JUL 1982, DOI: 10.1038/clpt.1982.128

  16. COMPARISON OF THE CLINICAL ACTIVITY OF MESULERGINE AND PERGOLIDE IN THE TREATMENT OF HYPERPROLACTINAEMIA

    Clinical Endocrinology

    Volume 22, Issue 5, May 1985, Pages: 611–616, A. GROSSMAN, P-M. G. BOULOUX, R. LONERAGAN, LESLEY H. REES, J. A. H. WASS and G. M. BESSER

    Version of Record online : 17 MAR 2008, DOI: 10.1111/j.1365-2265.1985.tb02996.x

  17. LONGTERM PERGOLIDE TREATMENT OF ACROMEGALY

    Clinical Endocrinology

    Volume 19, Issue 6, December 1983, Pages: 711–719, PAT KENDALL-TAYLOR, GILL UPSTILL-GODDARD and D. COOK

    Version of Record online : 17 MAR 2008, DOI: 10.1111/j.1365-2265.1983.tb00049.x

  18. Comparison of hair follicle histology between horses with pituitary pars intermedia dysfunction and excessive hair growth and normal aged horses

    Veterinary Dermatology

    Volume 24, Issue 1, February 2013, Pages: 212–e47, Marie Innerå, Annette D. Petersen, Danielle R. Desjardins, Barbara A. Steficek, Edmund J. Rosser Jr and Harold C. Schott II

    Version of Record online : 19 JAN 2013, DOI: 10.1111/j.1365-3164.2012.01080.x

  19. Bromocriptine use and the risk of valvular heart disease

    Movement Disorders

    Volume 24, Issue 3, 15 February 2009, Pages: 344–349, Louis C.S. Tan, Kenneth K.C. Ng, Wing-Lok Au, Raymond K.K. Lee, Yiong-Huak Chan and Nigel C.K. Tan

    Version of Record online : 6 NOV 2008, DOI: 10.1002/mds.22228

  20. The dopamine-γ aminobutyric acid interaction in the striatum of the rat is differently regulated by dopamine D-1 and D-2 types of receptor: evidence obtained with rotational behavioural experiments

    Acta Physiologica Scandinavica

    Volume 129, Issue 3, March 1987, Pages: 371–380, M. HERRERA-MARSCHITZ and U. UNGERSTEDT

    Version of Record online : 8 DEC 2008, DOI: 10.1111/j.1748-1716.1987.tb08080.x